Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Retained Earnings (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Retained Earnings for 15 consecutive years, with $611.6 million as the latest value for Q1 2026.

  • For Q1 2026, Retained Earnings rose 88285.26% year-over-year to $611.6 million; the TTM value through Mar 2026 reached $611.6 million, up 88285.26%, while the annual FY2025 figure was $2.3 million, 99.58% down from the prior year.
  • Retained Earnings hit $611.6 million in Q1 2026 for Corcept Therapeutics, up from $2.3 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $619.1 million in Q3 2025 and bottomed at -$1.4 million in Q1 2022.
  • Average Retained Earnings over 5 years is $228.9 million, with a median of $245.2 million recorded in 2022.
  • Year-over-year, Retained Earnings tumbled 101.28% in 2022 and then soared 1034957.78% in 2024.
  • Corcept Therapeutics' Retained Earnings stood at $296.4 million in 2022, then tumbled by 99.79% to $609000.0 in 2023, then surged by 89183.25% to $543.7 million in 2024, then plummeted by 99.58% to $2.3 million in 2025, then skyrocketed by 26915.28% to $611.6 million in 2026.
  • According to Business Quant data, Retained Earnings over the past three periods came in at $611.6 million, $2.3 million, and $619.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.